Indications for Obinutuzumab

Obinutuzumab contains the active substance obinutuzumab, which is a cancer drug used to treat chronic lymphocytic leukemia and follicular lymphoma, which are rare diseases. Obinutuzumab is designated as an 'orphan drug' (a drug for rare diseases).

(1) Previously untreated chronic lymphocytic leukemia (CLL): Chronic lymphocytic leukemia is a cancer of B lymphocytes, a type of white blood cell. Otuzumab is used with chlorambucil (another cancer drug) in patients for whom the cancer drug fludarabine is not recommended;

(2) Follicular lymphoma (FL): Another cancer of B lymphocytes. Otuzumab is used with chemotherapy (other cancer drugs) in patients who have not previously received treatment for advanced FL. It is also used with the drug bendamustine in patients who have not responded to rituximab treatment, or whose cancer has progressed within 6 months of treatment. Otuzumab is used alone as maintenance therapy in follicular lymphoma once the disease responds to treatment.

The original drug of Otuzumab has been launched in China and has entered the scope of medical insurance, but it is only reimbursed for patients who meet the indications. Specifications The price of 1000mg (40ml)*1 bottle may be around 9,000 yuan, which is a strictly controlled drug. The price of the Turkish version of Otuzumab Specifications1000mg/40ml per box listed overseas may be around RMB 10,000 (the price may fluctuate due to the exchange rate). The ingredients of the original drugs sold domestically and abroad are basically the same. There is currently no generic version of Otuzumab produced and launched. For more drug information and specific prices, please consult the medical consultant of Yaode.